RHJA
KPTI icon

Rice Hall James & Associates’s Karyopharm Therapeutics KPTI Stock Holding History

Rice Hall James & Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60,606
Closed -$4.96M – 269
2022
Q3 		$4.96M Sell
60,606
-27,116
-31% -$2.03M 0.29% 84
2022
Q2 		$5.93M Sell
87,722
-1,940
-2% -$178K 0.29% 75
2022
Q1 		$9.91M Buy
89,662
+4,553
+5% +$567K 0.4% 68
2021
Q4 		$8.21M Sell
85,109
-8,348
-9% -$832K 0.29% 73
2021
Q3 		$8.16M Sell
93,457
-503
-0.5% -$52.2K 0.3% 73
2021
Q2 		$14.5M Sell
93,960
-10,243
-10% -$1.49M 0.52% 59
2021
Q1 		$16.4M Buy
104,203
+703
+0.7% +$148K 0.54% 53
2020
Q4 		$24M Buy
103,500
+6,485
+7% +$1.5M 0.85% 39
2020
Q3 		$21.2M Buy
97,015
+46,227
+91% +$11.3M 0.86% 35
2020
Q2 		$14.4M Buy
50,788
+11,005
+28% +$3.25M 0.62% 50
2020
Q1 		$11.5M Buy
+39,783
New +$11M 0.64% 47

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rice Hall James & Associates's KPTI Position: Q4 2022 in Review

Rice Hall James & Associates sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 60,606 shares — an estimated $4.96M sold.

Rice Hall James & Associates first reported a position in KPTI in Q1 2020 and held it in 11 quarters. The position peaked at $24M in Q4 2020. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • Rice Hall James & Associates reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Rice Hall James & Associates sold 60,606 Karyopharm Therapeutics shares in Q4 2022, an estimated $4.96M.
  • Rice Hall James & Associates first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 11 quarters.
  • Rice Hall James & Associates's Karyopharm Therapeutics position peaked at $24M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on Rice Hall James & Associates's 13F filing for Q4 2022, filed 27 Jan 2023.